Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients
- 9 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 184 (1), 229-235
- https://doi.org/10.1007/s10549-020-05827-8
Abstract
Background The spectrum of BRCA1 and BRCA2 mutations in Slavic countries is characterized by a high prevalence of founder alleles. Methods We analyzed a large data set of Russian breast cancer (BC) and ovarian cancer (OC) patients, who were subjected to founder mutation tests or full-length BRCA1 and BRCA2 analysis. Results The most commonly applied test, which included four founder mutations (BRCA1: 5382insC, 4153delA, 185delAG; BRCA2: 6174delT), identified BRCA1 or BRCA2 heterozygosity in 399/8533 (4.7%) consecutive BC patients, 230/2317 (9.9%) OC patients, and 30/118 (25.4%) women with a combination of BC and OC. The addition of another four recurrent BRCA1 mutations to the test (BRCA1 C61G, 2080delA, 3819del5, 3875del4) resulted in evident increase in the number of identified mutation carriers (BC: 16/993 (1.6%); OC: 34/1289 (2.6%); BC + OC: 2/39 (5.1%)). Full-length sequencing of the entire BRCA1 and BRCA2 coding region was applied to 785 women, very most of whom demonstrated clinical signs of BRCA-driven disease, but turned out negative for all described above founder alleles. This analysis revealed additional BRCA1 or BRCA2 mutation carriers in 54/282 (19.1%) BC, 50/472 (10.6%) OC, and 13/31 (42%) BC + OC patients. The analysis of frequencies of founder and “rare” BRCA1 and BRCA2 pathogenic alleles across various clinical subgroups (BC vs. OC vs. BC + OC; family history positive vs. negative; young vs. late-onset; none vs. single vs. multiple clinical indicators of BRCA1- or BRCA2-associated disease) revealed that comprehensive BRCA1 and BRCA2 analysis increased more than twice the number of identified mutation carriers in all categories of the examined women. Conclusion Full-length BRCA1 and BRCA2 sequencing is strongly advised to Slavic subjects, who have medical indications for BRCA1 and BRCA2 testing but are negative for recurrent BRCA1 and BRCA2 mutations.Keywords
Funding Information
- Российский Фонд Фундаментальных Исследований (20-515-00002, 19-515-25001)
- Pfizer Foundation (56223641)
- Ministry of Science and Higher Education of the Russian Federation (075-15-2019-1669)
This publication has 28 references indexed in Scilit:
- BRCA mutation in ovarian cancer: testing, implications and treatment considerationsTherapeutic Advances in Medical Oncology, 2017
- Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic reviewThe American Journal of Surgery, 2016
- Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screeningAnnals Of Oncology, 2016
- Cytotoxic and targeted therapy for hereditary cancersHereditary Cancer in Clinical Practice, 2016
- Prevalence ofBRCA1/2germline mutations in 21 401 families with breast and ovarian cancerJournal of Medical Genetics, 2016
- Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patientsBreast Cancer Research and Treatment, 2014
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJama-Journal Of The American Medical Association, 2010
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- The Prevalence of Common BRCA1 and BRCA2 Mutations among Ashkenazi JewsAmerican Journal of Human Genetics, 1999